Karen Honey, PhD

As senior managing editor, science communications, Karen Honey, PhD, helps the AACR communicate scientific information to the public and educate the public about the importance of lifesaving cancer research. Before joining the AACR, Honey spent eight years working as an editor for two peer-reviewed scientific journals, first Nature Reviews Immunology and then The Journal of Clinical Investigation. During this time, she focused on communicating scientific discoveries to readers with all levels of knowledge, from the lay reader to the scientific expert. Before entering the world of science communication, Honey was a postdoctoral fellow in the laboratory of world-renowned immunologist Alexander Rudensky. She was born in the United Kingdom and received her doctorate in transplantation immunology from the University of Oxford. Honey currently lives in the Philadelphia suburbs.

AACR Blog Turns 4: How Far Has Immunotherapy Advanced in That Time?

This week marks the fourth anniversary of Cancer Research Catalyst, the official blog of the American Association for Cancer Research (AACR). As outlined in the welcome post from AACR Chief Executive Officer Margaret Foti, PhD, MD (hc), the blog was launched to increase the spread of new knowledge about cancer.

Over these four years, our blog posts have disseminated information about advances across the breadth of cancer research and the clinical cancer care continuum. One area in which advances have occurred at a particularly rapid pace is immunotherapy.

Read More

FDA Expands Use of Pembrolizumab to Two Additional Cancer Types

Last week, the U.S. Food and Drug Administration (FDA) increased the number of types of cancer for which pembrolizumab (Keytruda) is a treatment option when it approved the immunotherapeutic for treating certain patients with cervical cancer and certain patients with non-Hodgkin lymphoma.

Read More

FDA Approves Targeted Therapy Combo for Thyroid Cancer

On May 4, the U.S. Food and Drug Administration (FDA) approved a combination of molecularly targeted therapeutics for the treatment of a certain type of thyroid cancer. Specifically, the FDA approved the use of dabrafenib (Tafinlar) in combination with trametinib (Mekinist) for treating patients who have anaplastic thyroid cancer that cannot be removed by surgery or that has metastasized, and that tests positive for a BRAF V600E gene mutation.

Read More

Why We Need Tailored Tobacco-control Strategies

Cigarette smoking is linked to 18 different types of cancer. It is the leading preventable cause of cancer in the United States, accounting for 19 percent of the 1,570,978 cancers diagnosed in U.S. adults ages 30 and older in 2014, according to the latest research. Another 0.4 percent of the cancer diagnoses in the U.S. that year were attributable to exposure to secondhand smoke.

That’s why February, which is National Cancer Prevention Month, is a good time to raise awareness of the dangers of cigarette smoking and exposure to secondhand smoke.

Read More